Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis

Table 3 Comparison of serum fibroblast growth factor-23 and miR-208b in different subgroups of observation group

Group	n	Man, n (%)	Age (yr)	FGF-23 (ng/mL)	Relative expression of miR-208b	LAD (mm)	LVEDD (mm)	LVESD (mm)	LVEF (%)
Paroxysmal atrial fibrillation	134	98 (73.13)	61.02 ± 10.11	191.20 ± 65.59	4.88 ± 1.02	34.03 ± 4.02	50.03 ± 6.03	32.10 ± 5.58	53.30 ± 7.81
Persistent atrial fibrillation	106	70 (66.04)	59.89 ± 9.92	234.22 ± 70.05	5.83 ± 1.00	38.81 ± 5.11	49.81 ± 5.82	32.01 ± 6.02	52.83 ± 8.10
t		1.419	0.867	-4.896	-7.227	-8.112	0.285	0.120	0.455
P value		0.234	0.387	0.000	0.000	0.000	0.776	0.905	0.649

FGF: Fibroblast growth factor; LAD: Left atrial dimension; LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; LVESD: Left ventricular end-systolic diameter.